查看文章

Methods

The included studies compared TM with CD and reported clinical success for both methods. A random-effects model was used to determine the pooled odds ratios (ORs) and the 95% confidence intervals (CIs) for the following outcomes: technical success, clinical success, complications, and recurrence.

Results

Nine studies involving a combined total of 604 drainage procedures—373 TMs (62%) and 231 CDs (38%)—were included. CD showed no additional benefit over TM in terms of technical success (OR, 1.12; 95% CI, 0.37–3.37; p= 0.85), clinical success (OR, 1.11; 95% CI, 0.65–1.89; p= 0.70), recurrence (OR, 1.49; 95% CI, 0.53–4.21; p= 0.45), or complications (OR, 1.15; 95% CI, 0.61–2.18; p= 0.67).

Conclusions

Pancreatic duct (PD) stenting provides no additional clinical benefit for the TM of PFCs (particularly pseudocysts). Patients undergoing the TM of symptomatic pseudocysts may not require endoscopic retrograde pancreatography (ERP).